425: Personalis to be Acquired by Tempus AI in Merger Deal

Personalis, Inc. announced a definitive agreement to merge with Tempus AI, Inc. in a transaction structured as a two-step merger, with Tempus AI as the acquirer.

Summary

• Personalis, Inc. has entered into an Agreement and Plan of Merger with Tempus AI, Inc. (Parent) and its subsidiaries, Aviary Development, Inc. and Toucan Development, LLC.
• The transaction is structured as a two-step merger: first, Merger Sub I will merge with Personalis, and then the surviving entity will merge with Merger Sub II.
• The parties intend for the transaction to qualify as a reorganization under Section 368(a) of the U.S. Internal Revenue Code.
• Upon closing, Personalis stockholders will receive shares of Tempus AI Class A Common Stock, with an option for Tempus AI to elect to pay cash for up to 50% of the aggregate shares.
• The exchange ratio for the stock consideration will be fixed at 0.3356 if the Parent Stock Price is at or below $48.42, or calculated as $16.25 divided by the Parent Stock Price if it's above $48.42.
• Company equity awards, including options and RSUs, will be treated according to specific provisions, with some being cancelled, some converted to Tempus AI awards, and some accelerated.
• Closing conditions include stockholder approval, Nasdaq listing approval for Tempus AI shares, effectiveness of a Form S-4 registration statement, and absence of material adverse effects.
• Merck Sharp & Dohme LLC, holding approximately 13% of Personalis's outstanding voting power, has entered into a Voting Agreement to support the merger.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive development, as it signifies a strategic acquisition that could unlock value, but the success is contingent on closing conditions and integration.

Positives

• The merger agreement has been approved by the boards of directors of both Personalis and Tempus AI.
• Tempus AI has the option to elect to pay cash for up to 50% of the aggregate shares, potentially providing liquidity to Personalis stockholders.
• The transaction is structured to qualify as a reorganization for U.S. federal income tax purposes, which is generally favorable for tax treatment.
• Merck Sharp & Dohme LLC, a significant stockholder, has agreed to vote its shares in favor of the merger, indicating strong support.
• The shares of Parent Class A Common Stock to be issued as Stock Consideration will be listed on Nasdaq.

Negatives

• The merger is subject to customary closing conditions, including the approval of Personalis stockholders, which may not be obtained.
• There is a risk that a condition to closing may not be satisfied, or that either party may terminate the merger agreement.
• The company has agreed to customary no-shop restrictions, limiting its ability to solicit alternative acquisition proposals.
• Personalis will be required to pay a termination fee of approximately $76.8 million to Tempus AI under specified circumstances, including if the company's board changes its recommendation.
• Tempus AI will be required to pay a reverse termination fee of approximately $76.8 million under certain specified circumstances, such as termination due to antitrust issues caused by Tempus's breach.

Risks

• The possibility that stockholders of Personalis may not approve the merger agreement.
• The risk that a condition to closing of the transaction may not be satisfied (or waived), that either party may terminate the merger agreement, or that the closing of the transaction might be delayed or not occur at all.
• Potential adverse reactions or changes to business or employee relationships resulting from the announcement or completion of the transaction.
• The diversion of management time on transaction-related issues.
• The response of competitors to the proposed transaction.
• The ultimate timing, outcome, and results of integrating the operations of Tempus AI and Personalis.
• Regulatory approval and clearances of the transaction may not be obtained.
• Operating costs and business disruption may be greater than expected following the public announcement or consummation of the transaction.

Future Outlook

The filing contains forward-looking statements regarding the anticipated benefits of the proposed transaction, the anticipated impact on the combined company's business and future financial and operating results, expected synergies, and the anticipated closing date. However, it also cautions that it is uncertain whether these events will transpire or occur, and that actual results could differ materially due to various risks and uncertainties.

Management Comments

• The Company's Board of Directors has approved the Merger Agreement and resolved to recommend to stockholders to adopt the Merger Agreement.
• The Merger Agreement includes representations, warranties, and covenants customary for a transaction of this nature.
• The Company has agreed to customary no-shop restrictions, but may, under certain circumstances, provide information to and engage in discussions with third parties regarding a superior proposal.
• The Company's Board of Directors is permitted to make a Company Adverse Change Recommendation in response to a Superior Proposal or a Change in Circumstance, subject to notice and matching rights for Parent.

Industry Context

StockSavvy.ai notes that this merger represents a significant consolidation trend within the genomics and personalized medicine sector, where companies are increasingly seeking scale and integrated capabilities to compete effectively. The acquisition of Personalis by Tempus AI, a player in AI-driven precision medicine, suggests a strategic move to combine genomic data with advanced analytics for broader clinical applications.

Corporate Governance

Legal Proceedings

• The Merger Agreement includes provisions for specific performance as a remedy for both parties.
• The Merger Agreement includes customary termination provisions for both the Company and Parent.
• A termination fee of approximately $76.8 million is payable by Personalis to Tempus AI under specified circumstances.
• A reverse termination fee of approximately $76.8 million is payable by Tempus AI to Personalis under specified circumstances, including antitrust issues caused by Tempus's breach.

Related Party Transactions

• Merck Sharp & Dohme LLC, a stockholder of Personalis, entered into a Voting Agreement to support the merger.
• Information regarding the direct or indirect interests of Personalis's directors and executive officers in the transaction will be detailed in SEC filings.

Stakeholder Impact

• Shareholders: Will receive Tempus AI Class A Common Stock or cash, subject to the exchange ratio and potential cash election by Tempus AI. Their voting rights are crucial for deal approval.
• Employees: Company equity awards (options, RSUs, PSUs) will be treated according to the merger agreement, with some being cancelled, converted, or accelerated. Future employment with the combined entity is implied.
• Management: Management's time is noted as potentially diverted to transaction-related issues. Their interests in the transaction will be disclosed.
• Suppliers/Creditors: No direct impact is detailed, but potential changes in business operations or financial stability of the combined entity could indirectly affect them.

Next Steps

• Personalis stockholders must approve the Merger Agreement.
• Tempus AI must file a registration statement on Form S-4 with the SEC.
• A joint transaction statement on Schedule 13E-3 will be filed with the SEC.
• The proxy statement/prospectus will be sent to Personalis stockholders seeking their approval.
• The parties must satisfy all closing conditions, including regulatory approvals.
• The merger is expected to close, subject to the satisfaction of all conditions.

Key Dates

Recommendation

The filing announces a definitive merger agreement, which is a significant event. However, the terms are subject to closing conditions, including stockholder approval, and the ultimate value depends on the exchange ratio calculation and the future performance of Tempus AI. Given the uncertainties and the need for further information on the combined entity's prospects, a 'hold' recommendation is prudent pending further developments and analysis of the proxy statement/prospectus.

Keywords

merger agreement, acquisition, Tempus AI, Personalis, stockholders, merger, Class A Common Stock, Form 8-K